{
    "id": 91,
    "premise": "none",
    "hypothesis": "[PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage",
    "label": "entailment",
    "explanation": "[PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair.\nPARP1 and PARP2 are both involved in polyADP-ribosylation which is important in processes including recovery from DNA damage.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "[PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage",
        "history explanation": [
            "0 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair.\nPARP1 and PARP2 are both involved in polyADP-ribosylation which is important in processes including recovery from DNA damage.",
            "1 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, which is important in processes including recovery from DNA damage.",
            "2 iteration: [PARP1/2] inhibitors are a class of anticancer agents that specifically target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, which involves polyADP-ribosylation.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage, and this process is disrupted by [PARP1/2] inhibitors to target tumor-specific defects.",
            "3 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage. This process is disrupted by [PARP1/2] inhibitors, which is a mechanism to target tumor-specific defects.",
            "4 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage. This process is disrupted by [PARP1/2] inhibitors, which is a mechanism to target tumor-specific defects.\nInterfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair.",
            "5 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage. This process is disrupted by [PARP1/2] inhibitors, which interferes with the role of PARP1/2 in recovery from DNA damage.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair.\nInterfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair.",
            "6 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair.\nInterfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors is a direct mechanism that leads to targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage.",
            "7 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair.\nInterfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly leads to the inhibition of the recovery process from DNA damage, thereby targeting tumor-specific defects in DNA repair through the role of PARP1/",
            "8 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair.\nInterfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly leads to the inhibition of the recovery process from DNA damage, thereby targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage.",
            "9 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair.\nInterfering with the role of PARP1/2 in recovery from DNA damage directly leads to the targeting of tumor-specific defects in DNA repair, as it prevents the repair of DNA damage in tumor cells.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly leads to the inhibition of the recovery process from DNA damage, thereby targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage.",
            "10 iteration: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation.\nPARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair.\nInterfering with the role of PARP1/2 in recovery from DNA damage directly leads to the targeting of tumor-specific defects in DNA repair, as it prevents the repair of DNA damage in tumor cells.\nDisrupting polyADP-ribosylation by [PARP1/2] inhibitors directly leads to the inhibition of the recovery process from DNA damage, thereby targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage.\nThe role of PARP1/2 in recovery from DNA damage is essential for targeting tumor-specific defects, as it involves the repair mechanisms that are disrupted by [PARP1/2] inhibitors."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides that [PARP1/2] inhibitors target tumor-specific defects in DNA repair. *)\\n(* This implies that there exists an event e1 where Inhibitor x is the agent, TumourSpecificDefect y is the patient, and y is in z. *)\\nfrom explanation_1 have \"\u2203e1. Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z\" sledgehammer', 'solving time': 103.61322569847107, 'proof tactics': [], 'code': 'theory clinical_91_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  AnticancerAgent :: \"entity \u21d2 bool\"\\n  TumorSpecificDefect :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  Involved :: \"event \u21d2 bool\"\\n  Important :: \"event \u21d2 bool\"\\n  Process :: \"event \u21d2 bool\"\\n  Include :: \"event \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n  Role :: \"event \u21d2 bool\"\\n  Recover :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Inhibitor x \u2227 AnticancerAgent x \u2227 TumorSpecificDefect y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation which is important in processes including recovery from DNA damage. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. PARP1 x \u2227 PARP2 y \u2227 PolyADPRibosylation z \u2227 Involved e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 In x z \u2227 Important e2 \u2227 Process e2 \u2227 Include e2 z \u2227 Recovery e2 \u2227 From e2 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitor x \u2227 TumourSpecificDefect y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage. *)\\n  shows \"\u2203x y z e1 e2. Inhibitor x \u2227 TumourSpecificDefect y \u2227 DNARepair z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Role e2 \u2227 Agent e2 x \u2227 Recover e2 \u2227 From e2 y\"\\nproof -\\n  (* From the known information, we have Inhibitor x, TumourSpecificDefect y, and DNARepair z. *)\\n  from asm have \"Inhibitor x \u2227 TumourSpecificDefect y \u2227 DNARepair z\" <ATP>\\n  \\n  (* Explanation 1 provides that [PARP1/2] inhibitors target tumor-specific defects in DNA repair. *)\\n  (* This implies that there exists an event e1 where Inhibitor x is the agent, TumourSpecificDefect y is the patient, and y is in z. *)\\n  from explanation_1 have \"\u2203e1. Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z\" <ATP>\\n  \\n  (* Explanation 2 provides that PARP1 and PARP2 are involved in polyADP-ribosylation, which is important in processes including recovery from DNA damage. *)\\n  (* This implies the existence of an event e2 where the role of PARP1/2 is involved in recovery from DNA damage. *)\\n  from explanation_2 have \"\u2203e2. Role e2 \u2227 Agent e2 x \u2227 Recover e2 \u2227 From e2 y\" <ATP>\\n  \\n  (* Combining the results from explanation_1 and explanation_2, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors are a class of anticancer agents (from Explanatory Sentence 1)\\nB: target tumor-specific defects in DNA repair (from Explanatory Sentence 1)\\nC: PARP1 is involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nD: PARP2 is involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nE: polyADP-ribosylation is important in processes including recovery from DNA damage (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, target tumor-specific defects in DNA repair)\\n--------\\nAnd(C, D)\\nC & D\\n--------\\nImplies(And(C, D), E)\\nImplies(C & D, polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(A))\\nImplies(Not(polyADP-ribosylation is important in processes including recovery from DNA damage), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(polyADP-ribosylation is important in processes including recovery from DNA damage), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), Not(PARP2 is involved in polyADP-ribosylation))\\n--------\\nImplies(Not(B), E)\\nImplies(Not(target tumor-specific defects in DNA repair), polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\nImplies(C, E)\\nImplies(PARP1 is involved in polyADP-ribosylation, polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\nImplies(Not(D), Not(E))\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), Not(polyADP-ribosylation is important in processes including recovery from DNA damage))\\n--------\\nImplies(Not(D), D)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(D, C)\\nImplies(PARP2 is involved in polyADP-ribosylation, PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), C)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(E, C)\\nImplies(polyADP-ribosylation is important in processes including recovery from DNA damage, PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(A), C)\\nImplies(Not([PARP1/2] inhibitors are a class of anticancer agents), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(C, D)\\nImplies(PARP1 is involved in polyADP-ribosylation, PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(C), A)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), [PARP1/2] inhibitors are a class of anticancer agents)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(B), D)\\nImplies(Not(target tumor-specific defects in DNA repair), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(polyADP-ribosylation is important in processes including recovery from DNA damage), Not(PARP2 is involved in polyADP-ribosylation))\\n--------\\nImplies(D, E)\\nImplies(PARP2 is involved in polyADP-ribosylation, polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\nImplies(Not(C), E)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\nImplies(Not(A), E)\\nImplies(Not([PARP1/2] inhibitors are a class of anticancer agents), polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\nImplies(B, C)\\nImplies(target tumor-specific defects in DNA repair, PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(polyADP-ribosylation is important in processes including recovery from DNA damage), Not(PARP1 is involved in polyADP-ribosylation))\\n--------\\nImplies(Not(E), B)\\nImplies(Not(polyADP-ribosylation is important in processes including recovery from DNA damage), target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(E), C)\\nImplies(Not(polyADP-ribosylation is important in processes including recovery from DNA damage), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(A, C)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(E), A)\\nImplies(Not(polyADP-ribosylation is important in processes including recovery from DNA damage), [PARP1/2] inhibitors are a class of anticancer agents)\\n--------\\nImplies(B, E)\\nImplies(target tumor-specific defects in DNA repair, polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\nImplies(Not(C), D)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(E, D)\\nImplies(polyADP-ribosylation is important in processes including recovery from DNA damage, PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(A), D)\\nImplies(Not([PARP1/2] inhibitors are a class of anticancer agents), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(C), Not(E))\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), Not(polyADP-ribosylation is important in processes including recovery from DNA damage))\\n--------\\nImplies(Not(E), E)\\nImplies(Not(polyADP-ribosylation is important in processes including recovery from DNA damage), polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\nImplies(Not(D), B)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(A, E)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\nImplies(Not(C), Not(B))\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), Not(PARP1 is involved in polyADP-ribosylation))\\n--------\\nImplies(B, D)\\nImplies(target tumor-specific defects in DNA repair, PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), C)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), A)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), [PARP1/2] inhibitors are a class of anticancer agents)\\n--------\\nImplies(Not(E), D)\\nImplies(Not(polyADP-ribosylation is important in processes including recovery from DNA damage), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(target tumor-specific defects in DNA repair), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), E)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), polyADP-ribosylation is important in processes including recovery from DNA damage)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a logical relation: Implies(A, And(B, C)), which means [PARP1/2] inhibitors are a class of anticancer agents implies they target tumor-specific defects in DNA repair and interfere with the role of PARP1/2 in recovery from DNA damage. *)\\n(* Since we have Inhibitors x, we can infer the existence of an event e1 where Target e1, Agent e1 x, Patient e1 y, and In y z. *)\\nfrom explanation_1 have \"\u2203e1. Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z\" sledgehammer', 'solving time': 103.45796513557434, 'proof tactics': [], 'code': 'theory clinical_91_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitors :: \"entity \u21d2 bool\"\\n  AnticancerAgents :: \"entity \u21d2 bool\"\\n  Defects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  ClassOf :: \"entity \u21d2 entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  Role :: \"event \u21d2 entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  Involved :: \"event \u21d2 bool\"\\n  Important :: \"entity \u21d2 bool\"\\n  Processes :: \"entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  ThroughRole :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Inhibitors x \u2227 AnticancerAgents y \u2227 Defects z \u2227 DNARepair w \u2227 ClassOf x y \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 In z w \u2227 Interfere e2 \u2227 Role e2 w\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, which is important in processes including recovery from DNA damage. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PARP1 x \u2227 PARP2 y \u2227 PolyADPRibosylation z \u2227 Involved e \u2227 Agent e x \u2227 Agent e y \u2227 In x z \u2227 Important z \u2227 Processes z \u2227 Recovery z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage. *)\\n  shows \"\u2203x y z e. Inhibitors x \u2227 Defects y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 ThroughRole e z\"\\nproof -\\n  (* From the premise, we have known information about inhibitors, defects, and DNA repair. *)\\n  from asm have \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\" <ATP>\\n  (* Explanation 1 provides a logical relation: Implies(A, And(B, C)), which means [PARP1/2] inhibitors are a class of anticancer agents implies they target tumor-specific defects in DNA repair and interfere with the role of PARP1/2 in recovery from DNA damage. *)\\n  (* Since we have Inhibitors x, we can infer the existence of an event e1 where Target e1, Agent e1 x, Patient e1 y, and In y z. *)\\n  from explanation_1 have \"\u2203e1. Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z\" <ATP>\\n  (* Explanation 2 provides that PARP1 and PARP2 are involved in polyADP-ribosylation, which is important in recovery from DNA damage. *)\\n  (* We can use the derived implication: Implies(C, F), which means interfere with the role of PARP1/2 in recovery from DNA damage implies polyADP-ribosylation is important in recovery from DNA damage. *)\\n  (* Therefore, we can infer the existence of an event e2 where ThroughRole e2 z. *)\\n  from explanation_2 have \"\u2203e2. ThroughRole e2 z\" <ATP>\\n  (* Combining these, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors are a class of anticancer agents (from Explanatory Sentence 1)\\nB: target tumor-specific defects in DNA repair (from Explanatory Sentence 1)\\nC: interfere with the role of PARP1/2 in recovery from DNA damage (from Explanatory Sentence 1)\\nD: PARP1 is involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nE: PARP2 is involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nF: polyADP-ribosylation is important in recovery from DNA damage (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, B & C)\\n--------\\nAnd(D, E)\\nD & E\\n--------\\nImplies(And(D, E), F)\\nImplies(D & E, polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(A))\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), Not(PARP1 is involved in polyADP-ribosylation))\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(B), E)\\nImplies(Not(target tumor-specific defects in DNA repair), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(C, E)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(C, F)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(Not(F), B)\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(D), Not(E))\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), Not(PARP2 is involved in polyADP-ribosylation))\\n--------\\nImplies(Not(B), F)\\nImplies(Not(target tumor-specific defects in DNA repair), polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(Not(D), D)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), Not(C))\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(F, E)\\nImplies(polyADP-ribosylation is important in recovery from DNA damage, PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), C)\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(C, D)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(F), A)\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), [PARP1/2] inhibitors are a class of anticancer agents)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(B), D)\\nImplies(Not(target tumor-specific defects in DNA repair), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), Not(PARP1 is involved in polyADP-ribosylation))\\n--------\\nImplies(D, F)\\nImplies(PARP1 is involved in polyADP-ribosylation, polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(D, E)\\nImplies(PARP1 is involved in polyADP-ribosylation, PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(F, D)\\nImplies(polyADP-ribosylation is important in recovery from DNA damage, PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), E)\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), F)\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target tumor-specific defects in DNA repair), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(C), E)\\nImplies(Not(interfere with the role of PARP1/2 in recovery from DNA damage), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(A), E)\\nImplies(Not([PARP1/2] inhibitors are a class of anticancer agents), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(C), F)\\nImplies(Not(interfere with the role of PARP1/2 in recovery from DNA damage), polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(E, F)\\nImplies(PARP2 is involved in polyADP-ribosylation, polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(Not(A), F)\\nImplies(Not([PARP1/2] inhibitors are a class of anticancer agents), polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(A, B)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(E), C)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(A, C)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(Not(F), Not(E))\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), Not(PARP2 is involved in polyADP-ribosylation))\\n--------\\nImplies(Not(E), A)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), [PARP1/2] inhibitors are a class of anticancer agents)\\n--------\\nImplies(B, F)\\nImplies(target tumor-specific defects in DNA repair, polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(Not(F), D)\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(E), Not(F))\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), Not(polyADP-ribosylation is important in recovery from DNA damage))\\n--------\\nImplies(B, E)\\nImplies(target tumor-specific defects in DNA repair, PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(C), D)\\nImplies(Not(interfere with the role of PARP1/2 in recovery from DNA damage), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(E, D)\\nImplies(PARP2 is involved in polyADP-ribosylation, PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(A), D)\\nImplies(Not([PARP1/2] inhibitors are a class of anticancer agents), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(E), E)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(interfere with the role of PARP1/2 in recovery from DNA damage), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(A, F)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(A, E)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), Not(B))\\nImplies(Not(polyADP-ribosylation is important in recovery from DNA damage), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(Not(E), F)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\nImplies(B, D)\\nImplies(target tumor-specific defects in DNA repair, PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), C)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(Not(D), A)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), [PARP1/2] inhibitors are a class of anticancer agents)\\n--------\\nImplies(Not(D), Not(F))\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), Not(polyADP-ribosylation is important in recovery from DNA damage))\\n--------\\nImplies(Not(E), D)\\nImplies(Not(PARP2 is involved in polyADP-ribosylation), PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, PARP1 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), E)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), PARP2 is involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), F)\\nImplies(Not(PARP1 is involved in polyADP-ribosylation), polyADP-ribosylation is important in recovery from DNA damage)\\n--------\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a logical relation Implies(A, B), Implies([PARP1/2] inhibitors are a class of anticancer agents, target tumor-specific defects in DNA repair) *)\\n(* Since we have Inhibitors x, we can infer that they target tumor-specific defects in DNA repair. *)\\nthen have \"Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z\" sledgehammer', 'solving time': 103.397292137146, 'proof tactics': [], 'code': 'theory clinical_91_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitors :: \"entity \u21d2 bool\"\\n  AnticancerAgents :: \"entity \u21d2 bool\"\\n  Defects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  Role :: \"entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  FromDamage :: \"entity \u21d2 bool\"\\n  Involves :: \"entity \u21d2 entity \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  Involved :: \"event \u21d2 bool\"\\n  Process :: \"entity \u21d2 bool\"\\n  Crucial :: \"entity \u21d2 bool\"\\n  Disrupted :: \"event \u21d2 bool\"\\n  By :: \"event \u21d2 entity \u21d2 bool\"\\n  ThroughRole :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that specifically target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, which involves polyADP-ribosylation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Inhibitors x \u2227 AnticancerAgents x \u2227 Defects y \u2227 DNARepair z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Interfere e2 \u2227 Role w \u2227 Recovery w \u2227 FromDamage w \u2227 Involves w z \u2227 PolyADPRibosylation z\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage, and this process is disrupted by [PARP1/2] inhibitors to target tumor-specific defects. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. PARP1 x \u2227 PARP2 y \u2227 PolyADPRibosylation z \u2227 Involved e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 In x z \u2227 Process z \u2227 Crucial z \u2227 Recovery z \u2227 FromDamage z \u2227 Disrupted e2 \u2227 Agent e2 z \u2227 By e2 x \u2227 Target e2 \u2227 Defects y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage *)\\n  shows \"\u2203x y z e. Inhibitors x \u2227 Defects y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 ThroughRole e z\"\\nproof -\\n  (* From the premise, we have known information about inhibitors, defects, and DNA repair. *)\\n  from asm have \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\" <ATP>\\n  (* Explanation 1 provides a logical relation Implies(A, B), Implies([PARP1/2] inhibitors are a class of anticancer agents, target tumor-specific defects in DNA repair) *)\\n  (* Since we have Inhibitors x, we can infer that they target tumor-specific defects in DNA repair. *)\\n  then have \"Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z\" <ATP>\\n  (* Explanation 1 also provides that this targeting involves interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n  (* This interference is through the role of PARP1/2, which involves polyADP-ribosylation. *)\\n  then have \"ThroughRole e1 z\" <ATP>\\n  (* Combining these, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors are a class of anticancer agents (from Explanatory Sentence 1)\\nB: target tumor-specific defects in DNA repair (from Explanatory Sentence 1)\\nC: interfere with the role of PARP1/2 in recovery from DNA damage (from Explanatory Sentence 1)\\nD: involve polyADP-ribosylation (from Explanatory Sentence 1)\\nE: PARP1 and PARP2 are involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nF: polyADP-ribosylation is crucial for recovery from DNA damage (from Explanatory Sentence 2)\\nG: process disrupted by [PARP1/2] inhibitors (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, target tumor-specific defects in DNA repair)\\n--------\\nImplies(B, C)\\nImplies(target tumor-specific defects in DNA repair, interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(C, D)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, involve polyADP-ribosylation)\\n--------\\nImplies(E, F)\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(G, B)\\nImplies(process disrupted by [PARP1/2] inhibitors, target tumor-specific defects in DNA repair)\\n--------\\nEquivalent(D, E)\\nEquivalent(involve polyADP-ribosylation, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(G, Not(F))\\nImplies(process disrupted by [PARP1/2] inhibitors, Not(polyADP-ribosylation is crucial for recovery from DNA damage))\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(A))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(involve polyADP-ribosylation))\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(E), Not(G))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(A, Not(G))\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(C, E)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(C, F)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(G, Not(D))\\nImplies(process disrupted by [PARP1/2] inhibitors, Not(involve polyADP-ribosylation))\\n--------\\nImplies(Not(D), Not(E))\\nImplies(Not(involve polyADP-ribosylation), Not(PARP1 and PARP2 are involved in polyADP-ribosylation))\\n--------\\nImplies(Not(F), Not(C))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(involve polyADP-ribosylation), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(G, Not(C))\\nImplies(process disrupted by [PARP1/2] inhibitors, Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(involve polyADP-ribosylation), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(D), Not(G))\\nImplies(Not(involve polyADP-ribosylation), Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(involve polyADP-ribosylation))\\n--------\\nImplies(D, F)\\nImplies(involve polyADP-ribosylation, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(D, E)\\nImplies(involve polyADP-ribosylation, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(G, C)\\nImplies(process disrupted by [PARP1/2] inhibitors, interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(G, A)\\nImplies(process disrupted by [PARP1/2] inhibitors, [PARP1/2] inhibitors are a class of anticancer agents)\\n--------\\nImplies(C, Not(G))\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(G, E)\\nImplies(process disrupted by [PARP1/2] inhibitors, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(G, F)\\nImplies(process disrupted by [PARP1/2] inhibitors, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(A, C)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(G, D)\\nImplies(process disrupted by [PARP1/2] inhibitors, involve polyADP-ribosylation)\\n--------\\nImplies(B, E)\\nImplies(target tumor-specific defects in DNA repair, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(B, F)\\nImplies(target tumor-specific defects in DNA repair, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(E, D)\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, involve polyADP-ribosylation)\\n--------\\nImplies(D, Not(G))\\nImplies(involve polyADP-ribosylation, Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(interfere with the role of PARP1/2 in recovery from DNA damage), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(A, F)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(A, E)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), Not(B))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(F), Not(G))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(Not(C), Not(G))\\nImplies(Not(interfere with the role of PARP1/2 in recovery from DNA damage), Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(E, Not(G))\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(Not(A), Not(G))\\nImplies(Not([PARP1/2] inhibitors are a class of anticancer agents), Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(G, Not(E))\\nImplies(process disrupted by [PARP1/2] inhibitors, Not(PARP1 and PARP2 are involved in polyADP-ribosylation))\\n--------\\nImplies(B, D)\\nImplies(target tumor-specific defects in DNA repair, involve polyADP-ribosylation)\\n--------\\nImplies(G, Not(A))\\nImplies(process disrupted by [PARP1/2] inhibitors, Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(G, Not(B))\\nImplies(process disrupted by [PARP1/2] inhibitors, Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(G, Not(G))\\nImplies(process disrupted by [PARP1/2] inhibitors, Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, involve polyADP-ribosylation)\\n--------\\nImplies(B, Not(G))\\nImplies(target tumor-specific defects in DNA repair, Not(process disrupted by [PARP1/2] inhibitors))\\n--------\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a logical relation that [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n(* We can use the logical relation Implies(A, B) and Implies(A, C) from Explanation 1. *)\\n(* Since we have Inhibitors x, we can infer that they target tumor-specific defects in DNA repair and interfere with the role of PARP1/2 in recovery from DNA damage. *)\\nthen have \"Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 ThroughRole e z\" sledgehammer', 'solving time': 104.20630478858948, 'proof tactics': [], 'code': 'theory clinical_91_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitors :: \"entity \u21d2 bool\"\\n  AnticancerAgents :: \"entity \u21d2 bool\"\\n  Defects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  Role :: \"event \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"event \u21d2 entity \u21d2 bool\"\\n  Disrupt :: \"event \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  Involved :: \"entity \u21d2 entity \u21d2 bool\"\\n  Crucial :: \"entity \u21d2 event \u21d2 bool\"\\n  Process :: \"entity \u21d2 bool\"\\n  Mechanism :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Inhibitors x \u2227 AnticancerAgents y \u2227 Defects z \u2227 DNARepair w \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 In z w \u2227 Interfere e2 \u2227 Role e2 x \u2227 Recovery e2 w \u2227 Disrupt e2 \u2227 PolyADPRibosylation w\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. PARP1 x \u2227 PARP2 y \u2227 PolyADPRibosylation z \u2227 Involved x z \u2227 Involved y z \u2227 Crucial z e \u2227 Recovery e z\"\\n\\n(* Explanation 3: This process is disrupted by [PARP1/2] inhibitors, which is a mechanism to target tumor-specific defects. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Process x \u2227 Inhibitors y \u2227 Defects z \u2227 Disrupt e1 \u2227 Agent e1 y \u2227 Patient e1 x \u2227 Mechanism e2 \u2227 Target e2 \u2227 Patient e2 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage *)\\n  shows \"\u2203x y z e. Inhibitors x \u2227 Defects y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 ThroughRole e z\"\\nproof -\\n  (* From the premise, we have known information about inhibitors, defects, and DNA repair. *)\\n  from asm have \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\" <ATP>\\n  (* Explanation 1 provides a logical relation that [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n  (* We can use the logical relation Implies(A, B) and Implies(A, C) from Explanation 1. *)\\n  (* Since we have Inhibitors x, we can infer that they target tumor-specific defects in DNA repair and interfere with the role of PARP1/2 in recovery from DNA damage. *)\\n  then have \"Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 ThroughRole e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors are a class of anticancer agents (from Explanatory Sentence 1)\\nB: target tumor-specific defects in DNA repair (from Explanatory Sentence 1)\\nC: interfere with the role of PARP1/2 in recovery from DNA damage (from Explanatory Sentence 1)\\nD: disrupt polyADP-ribosylation (from Explanatory Sentence 1)\\nE: PARP1 and PARP2 are involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nF: polyADP-ribosylation is crucial for recovery from DNA damage (from Explanatory Sentence 2)\\nG: process is disrupted by [PARP1/2] inhibitors (from Explanatory Sentence 3)\\nH: mechanism to target tumor-specific defects (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, target tumor-specific defects in DNA repair)\\n--------\\nImplies(A, C)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(C, D)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, disrupt polyADP-ribosylation)\\n--------\\nAnd(E, F)\\nE & F\\n--------\\nImplies(G, H)\\nImplies(process is disrupted by [PARP1/2] inhibitors, mechanism to target tumor-specific defects)\\n--------\\nEquivalent(D, G)\\nEquivalent(disrupt polyADP-ribosylation, process is disrupted by [PARP1/2] inhibitors)\\n--------\\n\\nDerived Implications:\\nImplies(D, G)\\nImplies(disrupt polyADP-ribosylation, process is disrupted by [PARP1/2] inhibitors)\\n--------\\nImplies(Not(H), F)\\nImplies(Not(mechanism to target tumor-specific defects), polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(Not(E), Not(A))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(F), G)\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), process is disrupted by [PARP1/2] inhibitors)\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(E), Not(G))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(process is disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(disrupt polyADP-ribosylation))\\n--------\\nImplies(Not(B), E)\\nImplies(Not(target tumor-specific defects in DNA repair), PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(C, E)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(C, F)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(H, E)\\nImplies(mechanism to target tumor-specific defects, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), B)\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(G), Not(A))\\nImplies(Not(process is disrupted by [PARP1/2] inhibitors), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(B), F)\\nImplies(Not(target tumor-specific defects in DNA repair), polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(H, F)\\nImplies(mechanism to target tumor-specific defects, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(Not(F), Not(C))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(F, E)\\nImplies(polyADP-ribosylation is crucial for recovery from DNA damage, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(C, H)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, mechanism to target tumor-specific defects)\\n--------\\nImplies(Not(F), C)\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(Not(H), Not(A))\\nImplies(Not(mechanism to target tumor-specific defects), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(disrupt polyADP-ribosylation), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(Not(F), A)\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), [PARP1/2] inhibitors are a class of anticancer agents)\\n--------\\nImplies(Not(D), Not(G))\\nImplies(Not(disrupt polyADP-ribosylation), Not(process is disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(disrupt polyADP-ribosylation))\\n--------\\nImplies(D, F)\\nImplies(disrupt polyADP-ribosylation, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(D, E)\\nImplies(disrupt polyADP-ribosylation, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(A, G)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, process is disrupted by [PARP1/2] inhibitors)\\n--------\\nImplies(Not(E), G)\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), process is disrupted by [PARP1/2] inhibitors)\\n--------\\nImplies(Not(F), F)\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(Not(F), E)\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(C), E)\\nImplies(Not(interfere with the role of PARP1/2 in recovery from DNA damage), PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(A), E)\\nImplies(Not([PARP1/2] inhibitors are a class of anticancer agents), PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(D, H)\\nImplies(disrupt polyADP-ribosylation, mechanism to target tumor-specific defects)\\n--------\\nImplies(Not(C), F)\\nImplies(Not(interfere with the role of PARP1/2 in recovery from DNA damage), polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(E, F)\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(Not(A), F)\\nImplies(Not([PARP1/2] inhibitors are a class of anticancer agents), polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(process is disrupted by [PARP1/2] inhibitors), Not(disrupt polyADP-ribosylation))\\n--------\\nImplies(Not(E), B)\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(F), H)\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), mechanism to target tumor-specific defects)\\n--------\\nImplies(G, E)\\nImplies(process is disrupted by [PARP1/2] inhibitors, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), Not(H))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(mechanism to target tumor-specific defects))\\n--------\\nImplies(Not(E), C)\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(G, F)\\nImplies(process is disrupted by [PARP1/2] inhibitors, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(Not(G), Not(C))\\nImplies(Not(process is disrupted by [PARP1/2] inhibitors), Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(Not(F), Not(E))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(PARP1 and PARP2 are involved in polyADP-ribosylation))\\n--------\\nImplies(Not(E), A)\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), [PARP1/2] inhibitors are a class of anticancer agents)\\n--------\\nImplies(B, F)\\nImplies(target tumor-specific defects in DNA repair, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(Not(F), D)\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), disrupt polyADP-ribosylation)\\n--------\\nImplies(Not(E), Not(F))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(polyADP-ribosylation is crucial for recovery from DNA damage))\\n--------\\nImplies(B, E)\\nImplies(target tumor-specific defects in DNA repair, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(H), Not(D))\\nImplies(Not(mechanism to target tumor-specific defects), Not(disrupt polyADP-ribosylation))\\n--------\\nImplies(Not(E), E)\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not([PARP1/2] inhibitors are a class of anticancer agents))\\n--------\\nImplies(A, E)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(A, F)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(Not(H), Not(C))\\nImplies(Not(mechanism to target tumor-specific defects), Not(interfere with the role of PARP1/2 in recovery from DNA damage))\\n--------\\nImplies(Not(F), Not(B))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(target tumor-specific defects in DNA repair))\\n--------\\nImplies(Not(F), Not(G))\\nImplies(Not(polyADP-ribosylation is crucial for recovery from DNA damage), Not(process is disrupted by [PARP1/2] inhibitors))\\n--------\\nImplies(G, D)\\nImplies(process is disrupted by [PARP1/2] inhibitors, disrupt polyADP-ribosylation)\\n--------\\nImplies(Not(E), F)\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(C, G)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, process is disrupted by [PARP1/2] inhibitors)\\n--------\\nImplies(Not(E), Not(H))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(mechanism to target tumor-specific defects))\\n--------\\nImplies(Not(G), F)\\nImplies(Not(process is disrupted by [PARP1/2] inhibitors), polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(Not(G), E)\\nImplies(Not(process is disrupted by [PARP1/2] inhibitors), PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(E), H)\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), mechanism to target tumor-specific defects)\\n--------\\nImplies(A, H)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, mechanism to target tumor-specific defects)\\n--------\\nImplies(Not(E), D)\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), disrupt polyADP-ribosylation)\\n--------\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, disrupt polyADP-ribosylation)\\n--------\\nImplies(Not(H), E)\\nImplies(Not(mechanism to target tumor-specific defects), PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), E)\\nImplies(Not(disrupt polyADP-ribosylation), PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), F)\\nImplies(Not(disrupt polyADP-ribosylation), polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\n'}",
            "4 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a scenario where inhibitors target defects in DNA repair by interfering with the role of PARP1/2. *)\\n(* Explanation 4 states that interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which inhibitors target defects. *)\\n(* We have logical relations: Implies(E, A) and Implies(D, E). *)\\n(* From these, we can derive that disrupting polyADP-ribosylation (D) leads to targeting tumor-specific defects (A). *)\\n(* Therefore, we can infer that the inhibitors target tumor-specific defects in DNA repair through the role of PARP1/2. *)\\nthen have \"\u2203e. Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 ThroughRole e z\" sledgehammer', 'solving time': 103.25573110580444, 'proof tactics': [], 'code': 'theory clinical_91_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  AnticancerAgent :: \"entity \u21d2 bool\"\\n  Defect :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  Role :: \"event \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"event \u21d2 entity \u21d2 bool\"\\n  Disrupt :: \"event \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  Involved :: \"event \u21d2 bool\"\\n  Process :: \"entity \u21d2 bool\"\\n  Crucial :: \"entity \u21d2 bool\"\\n  Mechanism :: \"event \u21d2 bool\"\\n  ThroughRole :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2 e3. Inhibitor x \u2227 AnticancerAgent x \u2227 Defect y \u2227 DNARepair z \u2227 PolyADPRibosylation w \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Interfere e2 \u2227 Role e2 x \u2227 Recovery e2 z \u2227 Disrupt e3 \u2227 Through e3 w\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. PARP1 x \u2227 PARP2 y \u2227 PolyADPRibosylation z \u2227 Involved e \u2227 Agent e x \u2227 Agent e y \u2227 Process z \u2227 Crucial z \u2227 Recovery e z\"\\n\\n(* Explanation 3: This process is disrupted by [PARP1/2] inhibitors, which is a mechanism to target tumor-specific defects *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Process x \u2227 Inhibitor y \u2227 Defect z \u2227 Disrupt e1 \u2227 Agent e1 y \u2227 Patient e1 x \u2227 Mechanism e2 \u2227 Target e2 \u2227 Patient e2 z\"\\n\\n(* Explanation 4: Interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2. Interfere e1 \u2227 Role e1 x \u2227 Recovery e1 y \u2227 DNARepair y \u2227 Mechanism e2 \u2227 Inhibitor z \u2227 Defect w \u2227 Target e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 In w y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitor x \u2227 Defect y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage *)\\n  shows \"\u2203x y z e. Inhibitor x \u2227 Defect y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 ThroughRole e z\"\\nproof -\\n  (* From the premise, we have known information about the inhibitor, defect, and DNA repair. *)\\n  from asm have \"Inhibitor x \u2227 Defect y \u2227 DNARepair z\" <ATP>\\n  (* Explanation 1 provides a scenario where inhibitors target defects in DNA repair by interfering with the role of PARP1/2. *)\\n  (* Explanation 4 states that interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which inhibitors target defects. *)\\n  (* We have logical relations: Implies(E, A) and Implies(D, E). *)\\n  (* From these, we can derive that disrupting polyADP-ribosylation (D) leads to targeting tumor-specific defects (A). *)\\n  (* Therefore, we can infer that the inhibitors target tumor-specific defects in DNA repair through the role of PARP1/2. *)\\n  then have \"\u2203e. Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 ThroughRole e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors target tumor-specific defects in DNA repair (from Explanatory Sentence 1)\\nB: PARP1/2 are involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nC: PolyADP-ribosylation is crucial for recovery from DNA damage (from Explanatory Sentence 2)\\nD: [PARP1/2] inhibitors disrupt polyADP-ribosylation (from Explanatory Sentence 1 and 3)\\nE: Interfering with the role of PARP1/2 in recovery from DNA damage (from Explanatory Sentence 1 and 4)\\n\\nLogical Relations:\\nImplies(D, E)\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Interfering with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(E, A)\\nImplies(Interfering with the role of PARP1/2 in recovery from DNA damage, [PARP1/2] inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(B, C)\\nImplies(PARP1/2 are involved in polyADP-ribosylation, PolyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(D, Not(C))\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Not(PolyADP-ribosylation is crucial for recovery from DNA damage))\\n--------\\n\\nDerived Implications:\\nImplies(D, A)\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, [PARP1/2] inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not([PARP1/2] inhibitors target tumor-specific defects in DNA repair), Not([PARP1/2] inhibitors disrupt polyADP-ribosylation))\\n--------\\nImplies(D, Not(B))\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Not(PARP1/2 are involved in polyADP-ribosylation))\\n--------\\nImplies(B, Not(D))\\nImplies(PARP1/2 are involved in polyADP-ribosylation, Not([PARP1/2] inhibitors disrupt polyADP-ribosylation))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a logical relation: Implies(A, B), Implies(A, C), and Implies(A, D). *)\\n(* Explanation 4 and 5 provide the necessary link between disrupting polyADP-ribosylation and targeting defects. *)\\n(* Using Implies(D, C) and Implies(C, B), we can infer that disrupting polyADP-ribosylation leads to targeting tumor-specific defects. *)\\nfrom explanation_4 have \"\u2203e1 e2. Disrupt e1 \u2227 Agent e1 x \u2227 Interfere e2 \u2227 Agent e2 x \u2227 With e2 r \u2227 RoleOfPARP1_2 r \u2227 Mechanism e2 z \u2227 TargetingDefects z\" sledgehammer', 'solving time': 103.31539273262024, 'proof tactics': [], 'code': 'theory clinical_91_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitors :: \"entity \u21d2 bool\"\\n  AnticancerAgents :: \"entity \u21d2 bool\"\\n  ClassOf :: \"entity \u21d2 entity \u21d2 bool\"\\n  Defects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  With :: \"event \u21d2 entity \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  RoleOfPARP1_2 :: \"entity \u21d2 bool\"\\n  DisruptingPolyADP_ribosylation :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  PolyADP_ribosylation :: \"entity \u21d2 bool\"\\n  InvolvedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  CrucialFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  RecoveryFromDNADamage :: \"entity \u21d2 bool\"\\n  Process :: \"entity \u21d2 bool\"\\n  Disrupt :: \"event \u21d2 bool\"\\n  Mechanism :: \"event \u21d2 entity \u21d2 bool\"\\n  TargetingDefects :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Inhibitors x \u2227 AnticancerAgents y \u2227 ClassOf x y \u2227 Defects z \u2227 DNARepair w \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 In z w \u2227 Interfere e2 \u2227 Agent e2 x \u2227 With e2 r \u2227 RoleOfPARP1_2 r \u2227 Through e2 d \u2227 DisruptingPolyADP_ribosylation d\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. (PARP1 x \u2228 PARP2 x) \u2227 PolyADP_ribosylation y \u27f6 (InvolvedIn x y \u2227 CrucialFor y z \u2227 RecoveryFromDNADamage z)\"\\n\\n(* Explanation 3: This process is disrupted by [PARP1/2] inhibitors, which interferes with the role of PARP1/2 in recovery from DNA damage *)\\naxiomatization where\\n  explanation_3: \"\u2203x y e1 e2. Process x \u2227 Inhibitors y \u2227 Disrupt e1 \u2227 Agent e1 y \u2227 Patient e1 x \u2227 Interfere e2 \u2227 Agent e2 y \u2227 With e2 r \u2227 RoleOfPARP1_2 r\"\\n\\n(* Explanation 4: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2. PolyADP_ribosylation x \u2227 Inhibitors y \u2227 Disrupt e1 \u2227 Agent e1 y \u2227 Patient e1 x \u2227 Interfere e2 \u2227 Agent e2 y \u2227 With e2 r \u2227 RoleOfPARP1_2 r \u2227 Mechanism e2 z \u2227 TargetingDefects z \u2227 Defects z \u2227 In z w \u2227 DNARepair w\"\\n\\n(* Explanation 5: Interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. RoleOfPARP1_2 x \u2227 Interfere e1 \u2227 With e1 x \u2227 Mechanism e1 z \u2227 TargetingDefects z \u2227 Inhibitors y \u2227 Defects z \u2227 DNARepair z \u2227 Target e2 \u2227 Agent e2 y \u2227 Patient e2 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage *)\\n  shows \"\u2203x y z e. Inhibitors x \u2227 Defects y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e r \u2227 RoleOfPARP1_2 r\"\\nproof -\\n  (* From the premise, we have known information about inhibitors, defects, and DNA repair. *)\\n  from asm have \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\" <ATP>\\n  (* Explanation 1 provides a logical relation: Implies(A, B), Implies(A, C), and Implies(A, D). *)\\n  (* Explanation 4 and 5 provide the necessary link between disrupting polyADP-ribosylation and targeting defects. *)\\n  (* Using Implies(D, C) and Implies(C, B), we can infer that disrupting polyADP-ribosylation leads to targeting tumor-specific defects. *)\\n  from explanation_4 have \"\u2203e1 e2. Disrupt e1 \u2227 Agent e1 x \u2227 Interfere e2 \u2227 Agent e2 x \u2227 With e2 r \u2227 RoleOfPARP1_2 r \u2227 Mechanism e2 z \u2227 TargetingDefects z\" <ATP>\\n  (* From the above, we can infer that there exists an event e such that the inhibitors target defects through the role of PARP1/2. *)\\n  then have \"\u2203e. Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e r \u2227 RoleOfPARP1_2 r\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors are a class of anticancer agents (from Explanatory Sentence 1)\\nB: target tumor-specific defects in DNA repair (from Explanatory Sentence 1)\\nC: interfere with the role of PARP1/2 in recovery from DNA damage (from Explanatory Sentence 1)\\nD: disrupt polyADP-ribosylation (from Explanatory Sentence 1)\\nE: PARP1 and PARP2 are involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nF: polyADP-ribosylation is crucial for recovery from DNA damage (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, target tumor-specific defects in DNA repair)\\n--------\\nImplies(A, C)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors are a class of anticancer agents, disrupt polyADP-ribosylation)\\n--------\\nImplies(E, F)\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, polyADP-ribosylation is crucial for recovery from DNA damage)\\n--------\\nImplies(D, C)\\nImplies(disrupt polyADP-ribosylation, interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(C, B)\\nImplies(interfere with the role of PARP1/2 in recovery from DNA damage, target tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(Not(B), Not(D))\\nImplies(Not(target tumor-specific defects in DNA repair), Not(disrupt polyADP-ribosylation))\\n--------\\nImplies(D, B)\\nImplies(disrupt polyADP-ribosylation, target tumor-specific defects in DNA repair)\\n--------\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a scenario where [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n(* Explanation 5 states that disrupting polyADP-ribosylation by [PARP1/2] inhibitors is a direct mechanism that leads to targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage. *)\\n(* Using explanation_5, we can infer the existence of such a targeting event. *)\\nfrom explanation_5 obtain e1 e2 where \"Inhibitor x \u2227 PolyADPRibosylation y \u2227 Defect z \u2227 Repair z \u2227 Role e1 w \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 x \u2227 Target e2 \u2227 Patient e2 z \u2227 Through e2 w\" sledgehammer', 'solving time': 103.18602967262268, 'proof tactics': [], 'code': 'theory clinical_91_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  AnticancerAgent :: \"entity \u21d2 bool\"\\n  Defect :: \"entity \u21d2 bool\"\\n  Repair :: \"entity \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  Role :: \"event \u21d2 entity \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  InvolvedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  Disrupt :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Inhibitor x \u2227 AnticancerAgent x \u2227 Defect y \u2227 Repair z \u2227 PolyADPRibosylation w \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Interfere e2 \u2227 Agent e2 x \u2227 Role e2 w \u2227 Through e2 w\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. (PARP1 x \u2228 PARP2 x) \u2227 PolyADPRibosylation y \u27f6 InvolvedIn x y\"\\n\\n(* Explanation 3: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Inhibitor x \u2227 PolyADPRibosylation y \u2227 Defect z \u2227 Repair z \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Interfere e2 \u2227 Agent e2 x \u2227 Role e2 y \u2227 Target e2 \u2227 Patient e2 z\"\\n\\n(* Explanation 4: Interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. Inhibitor x \u2227 Role e1 y \u2227 Defect z \u2227 Repair z \u2227 Interfere e1 \u2227 Agent e1 x \u2227 Role e1 y \u2227 Target e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 5: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors is a direct mechanism that leads to targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e1 e2. Inhibitor x \u2227 PolyADPRibosylation y \u2227 Defect z \u2227 Repair z \u2227 Role e1 w \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 x \u2227 Target e2 \u2227 Patient e2 z \u2227 Through e2 w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitor x \u2227 Defect y \u2227 Repair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage *)\\n  shows \"\u2203x y z e. Inhibitor x \u2227 Defect y \u2227 Repair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\"\\nproof -\\n  (* From the premise, we have known information about the inhibitor, defect, and repair. *)\\n  from asm have \"Inhibitor x \u2227 Defect y \u2227 Repair z\" <ATP>\\n  (* Explanation 1 provides a scenario where [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n  (* Explanation 5 states that disrupting polyADP-ribosylation by [PARP1/2] inhibitors is a direct mechanism that leads to targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage. *)\\n  (* Using explanation_5, we can infer the existence of such a targeting event. *)\\n  from explanation_5 obtain e1 e2 where \"Inhibitor x \u2227 PolyADPRibosylation y \u2227 Defect z \u2227 Repair z \u2227 Role e1 w \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 x \u2227 Target e2 \u2227 Patient e2 z \u2227 Through e2 w\" <ATP>\\n  (* We can conclude that there exists an event e such that the inhibitor targets the defect through the role of PARP1/2 in recovery from DNA damage. *)\\n  then have \"\u2203e. Target e \u2227 Agent e x \u2227 Patient e y \u2227 Through e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors disrupt polyADP-ribosylation (from Explanatory Sentence 1)\\nB: PARP1/2 are involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nC: Recovery from DNA damage (from Explanatory Sentence 2)\\nD: Targeting tumor-specific defects in DNA repair (from Explanatory Sentence 1)\\n\\nLogical Relations:\\nImplies(A, Not(B))\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Not(PARP1/2 are involved in polyADP-ribosylation))\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(PARP1/2 are involved in polyADP-ribosylation), Not(Recovery from DNA damage))\\n--------\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(C), D)\\nImplies(Not(Recovery from DNA damage), Targeting tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(C, Not(A))\\nImplies(Recovery from DNA damage, Not([PARP1/2] inhibitors disrupt polyADP-ribosylation))\\n--------\\nImplies(Not(B), D)\\nImplies(Not(PARP1/2 are involved in polyADP-ribosylation), Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(A, Not(C))\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Not(Recovery from DNA damage))\\n--------\\nImplies(Not(D), B)\\nImplies(Not(Targeting tumor-specific defects in DNA repair), PARP1/2 are involved in polyADP-ribosylation)\\n--------\\n'}",
            "7 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a logical relation that [PARP1/2] inhibitors disrupt polyADP-ribosylation, which targets tumor-specific defects in DNA repair. *)\\n(* This corresponds to logical proposition A and E, with the relation Implies(A, E). *)\\n(* Explanation 3 and 4 also support that interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism to target tumor-specific defects in DNA repair. *)\\n(* This corresponds to logical proposition D and E, with the relation Implies(D, E). *)\\n(* We can infer that the inhibitors target tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage. *)\\nthen have \"Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\" sledgehammer', 'solving time': 103.19393825531006, 'proof tactics': [], 'code': 'theory clinical_91_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitors :: \"entity \u21d2 bool\"\\n  AnticancerAgents :: \"entity \u21d2 bool\"\\n  ClassOf :: \"entity \u21d2 entity \u21d2 bool\"\\n  Defects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  RoleOf :: \"event \u21d2 entity \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  Disrupt :: \"event \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  InvolvedIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  CrucialFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Mechanism :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  RecoveryProcess :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Inhibitors x \u2227 AnticancerAgents y \u2227 ClassOf x y \u2227 Defects z \u2227 DNARepair w \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 In z w \u2227 Interfere e2 \u2227 Agent e2 x \u2227 RoleOf e2 w \u2227 Through e2 w \u2227 Disrupt e2\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z w. PARP1 x \u2227 PARP2 y \u2227 PolyADPRibosylation z \u2227 InvolvedIn x z \u2227 InvolvedIn y z \u2227 Recovery w \u2227 CrucialFor z w\"\\n\\n(* Explanation 3: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Inhibitors x \u2227 PolyADPRibosylation y \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Interfere e2 \u2227 Agent e2 x \u2227 RoleOf e2 y \u2227 Directly e2 \u2227 Mechanism e2 \u2227 Target e2 \u2227 Defects z \u2227 DNARepair z\"\\n\\n(* Explanation 4: Interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. Inhibitors x \u2227 RoleOf e1 y \u2227 Interfere e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Mechanism e1 \u2227 Target e2 \u2227 Agent e2 x \u2227 Defects z \u2227 DNARepair z\"\\n\\n(* Explanation 5: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly leads to the inhibition of the recovery process from DNA damage, thereby targeting tumor-specific defects in DNA repair through the role of PARP1/ *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e1 e2 e3. Inhibitors x \u2227 PolyADPRibosylation y \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 x \u2227 Inhibition z \u2227 RecoveryProcess z \u2227 Directly e2 \u2227 Target e3 \u2227 Agent e3 x \u2227 Defects w \u2227 DNARepair w \u2227 Through e3 y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage *)\\n  shows \"\u2203x y z e. Inhibitors x \u2227 Defects y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\"\\nproof -\\n  (* From the premise, we have known information about inhibitors, defects, and DNA repair. *)\\n  from asm have \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\" <ATP>\\n  (* Explanation 1 provides a logical relation that [PARP1/2] inhibitors disrupt polyADP-ribosylation, which targets tumor-specific defects in DNA repair. *)\\n  (* This corresponds to logical proposition A and E, with the relation Implies(A, E). *)\\n  (* Explanation 3 and 4 also support that interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism to target tumor-specific defects in DNA repair. *)\\n  (* This corresponds to logical proposition D and E, with the relation Implies(D, E). *)\\n  (* We can infer that the inhibitors target tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage. *)\\n  then have \"Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors disrupt polyADP-ribosylation (from Explanatory Sentence 1)\\nB: PARP1 and PARP2 are involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nC: Recovery from DNA damage (from Explanatory Sentence 2)\\nD: [PARP1/2] inhibitors interfere with the role of PARP1/2 in recovery from DNA damage (from Explanatory Sentence 3)\\nE: Targeting tumor-specific defects in DNA repair (from Explanatory Sentence 1 and 4)\\n\\nLogical Relations:\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, [PARP1/2] inhibitors interfere with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, Recovery from DNA damage)\\n--------\\nImplies(D, E)\\nImplies([PARP1/2] inhibitors interfere with the role of PARP1/2 in recovery from DNA damage, Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(A, E)\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Targeting tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\n'}",
            "8 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a logical relation that [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n(* Explanation 4 states that interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair. *)\\n(* We can use the logical relation Implies(B, A) from Explanation 1 and Explanation 4 to infer the target event. *)\\nthen have \"\u2203e. Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\" sledgehammer', 'solving time': 103.40826869010925, 'proof tactics': [], 'code': 'theory clinical_91_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitors :: \"entity \u21d2 bool\"\\n  AnticancerAgents :: \"entity \u21d2 bool\"\\n  Defects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  Role :: \"entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  Disrupt :: \"event \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  Involved :: \"event \u21d2 bool\"\\n  Process :: \"event \u21d2 entity \u21d2 bool\"\\n  Crucial :: \"entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  With :: \"event \u21d2 entity \u21d2 bool\"\\n  Mechanism :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Inhibition :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Inhibitors x \u2227 AnticancerAgents y \u2227 Defects z \u2227 DNARepair w \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 In z w \u2227 Interfere e2 \u2227 Agent e2 x \u2227 Role y \u2227 Recovery w \u2227 Through e2 w \u2227 Disrupt e2\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. PARP1 x \u2227 PARP2 y \u2227 PolyADPRibosylation z \u2227 Involved e \u2227 Agent e x \u2227 Agent e y \u2227 Process e z \u2227 Crucial z \u2227 Recovery z\"\\n\\n(* Explanation 3: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2. Inhibitors x \u2227 PolyADPRibosylation y \u2227 Role z \u2227 Recovery w \u2227 Interfere e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1 \u2227 With e1 z \u2227 Mechanism e2 \u2227 Target e2 \u2227 Defects w\"\\n\\n(* Explanation 4: Interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. Inhibitors x \u2227 Role y \u2227 Recovery z \u2227 Interfere e1 \u2227 Agent e1 x \u2227 With e1 y \u2227 Mechanism e2 \u2227 Target e2 \u2227 Defects z\"\\n\\n(* Explanation 5: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly leads to the inhibition of the recovery process from DNA damage, thereby targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e1 e2 e3. Inhibitors x \u2227 PolyADPRibosylation y \u2227 Recovery z \u2227 Process e3 w \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Directly e2 \u2227 Inhibition e2 z \u2227 Target e3 \u2227 Defects w \u2227 Through e3 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage *)\\n  shows \"\u2203x y z e. Inhibitors x \u2227 Defects y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\"\\nproof -\\n  (* From the premise, we have known information about inhibitors, defects, and DNA repair. *)\\n  from asm have \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\" <ATP>\\n  (* Explanation 1 provides a logical relation that [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n  (* Explanation 4 states that interfering with the role of PARP1/2 in recovery from DNA damage is a mechanism by which [PARP1/2] inhibitors target tumor-specific defects in DNA repair. *)\\n  (* We can use the logical relation Implies(B, A) from Explanation 1 and Explanation 4 to infer the target event. *)\\n  then have \"\u2203e. Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors target tumor-specific defects in DNA repair (from Explanatory Sentence 1)\\nB: Interfering with the role of PARP1/2 in recovery from DNA damage (from Explanatory Sentence 1)\\nC: Disrupting polyADP-ribosylation (from Explanatory Sentence 1)\\nD: PARP1 and PARP2 are involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nE: Recovery from DNA damage (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(C, B)\\nImplies(Disrupting polyADP-ribosylation, Interfering with the role of PARP1/2 in recovery from DNA damage)\\n--------\\nImplies(B, A)\\nImplies(Interfering with the role of PARP1/2 in recovery from DNA damage, [PARP1/2] inhibitors target tumor-specific defects in DNA repair)\\n--------\\nEquivalent(D, E)\\nEquivalent(PARP1 and PARP2 are involved in polyADP-ribosylation, Recovery from DNA damage)\\n--------\\nImplies(C, E)\\nImplies(Disrupting polyADP-ribosylation, Recovery from DNA damage)\\n--------\\nImplies(E, A)\\nImplies(Recovery from DNA damage, [PARP1/2] inhibitors target tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(D, A)\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, [PARP1/2] inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(Disrupting polyADP-ribosylation))\\n--------\\nImplies(C, D)\\nImplies(Disrupting polyADP-ribosylation, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(A), Not(D))\\nImplies(Not([PARP1/2] inhibitors target tumor-specific defects in DNA repair), Not(PARP1 and PARP2 are involved in polyADP-ribosylation))\\n--------\\nImplies(D, E)\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, Recovery from DNA damage)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(Recovery from DNA damage), Not(PARP1 and PARP2 are involved in polyADP-ribosylation))\\n--------\\nImplies(E, D)\\nImplies(Recovery from DNA damage, PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\nImplies(Not(D), Not(E))\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Not(Recovery from DNA damage))\\n--------\\nImplies(C, A)\\nImplies(Disrupting polyADP-ribosylation, [PARP1/2] inhibitors target tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(A), Not(C))\\nImplies(Not([PARP1/2] inhibitors target tumor-specific defects in DNA repair), Not(Disrupting polyADP-ribosylation))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a scenario where [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n(* Explanation 3 states that disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair. *)\\n(* Using the derived implication Implies(A, D), we know that disrupting polyADP-ribosylation leads to targeting tumor-specific defects in DNA repair. *)\\n(* Therefore, we can infer the existence of an event e that targets the defect y through the role of recovery z. *)\\nthen have \"\u2203e. Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\" sledgehammer', 'solving time': 103.34754061698914, 'proof tactics': [], 'code': 'theory clinical_91_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  AnticancerAgent :: \"entity \u21d2 bool\"\\n  Defect :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  Involved :: \"entity \u21d2 entity \u21d2 bool\"\\n  Disrupt :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Mechanism :: \"event \u21d2 entity \u21d2 bool\"\\n  Role :: \"entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  TumorCell :: \"entity \u21d2 bool\"\\n  Inhibition :: \"event \u21d2 bool\"\\n  Process :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Inhibitor x \u2227 AnticancerAgent x \u2227 Defect y \u2227 DNARepair z \u2227 PolyADPRibosylation w \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Interfere e2 \u2227 Agent e2 x \u2227 Patient e2 w \u2227 Through e2 w\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. PARP1 x \u2227 PARP2 y \u2227 PolyADPRibosylation z \u27f6 (Involved x z \u2227 Involved y z)\"\\n\\n(* Explanation 3: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Inhibitor x \u2227 PolyADPRibosylation y \u2227 Defect z \u2227 DNARepair w \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Interfere e2 \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Directly e2 \u2227 Mechanism e2 z \u2227 Target e2 \u2227 In z w\"\\n\\n(* Explanation 4: Interfering with the role of PARP1/2 in recovery from DNA damage directly leads to the targeting of tumor-specific defects in DNA repair, as it prevents the repair of DNA damage in tumor cells *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2 e3. Interfere e1 \u2227 Role x \u2227 Recovery y \u2227 DNARepair z \u2227 Directly e1 \u2227 Lead e2 \u2227 Target e2 \u2227 Defect z \u2227 In z y \u2227 Prevent e3 \u2227 Repair e3 \u2227 DNA x \u2227 TumorCell y\"\\n\\n(* Explanation 5: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly leads to the inhibition of the recovery process from DNA damage, thereby targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e1 e2 e3. Inhibitor x \u2227 PolyADPRibosylation y \u2227 Recovery z \u2227 DNARepair w \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1 \u2227 Lead e2 \u2227 Inhibition e2 \u2227 Process z \u2227 Target e3 \u2227 Defect w \u2227 Through e3 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitor x \u2227 Defect y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage *)\\n  shows \"\u2203x y z e. Inhibitor x \u2227 Defect y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\"\\nproof -\\n  (* From the premise, we have known information about the inhibitor, defect, and DNA repair. *)\\n  from asm have \"Inhibitor x \u2227 Defect y \u2227 DNARepair z\" <ATP>\\n  (* Explanation 1 provides a scenario where [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n  (* Explanation 3 states that disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair. *)\\n  (* Using the derived implication Implies(A, D), we know that disrupting polyADP-ribosylation leads to targeting tumor-specific defects in DNA repair. *)\\n  (* Therefore, we can infer the existence of an event e that targets the defect y through the role of recovery z. *)\\n  then have \"\u2203e. Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors disrupt polyADP-ribosylation (from Explanatory Sentence 1)\\nB: PARP1/2 are involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nC: Recovery from DNA damage (from Explanatory Sentence 1 and 2)\\nD: Targeting tumor-specific defects in DNA repair (from Explanatory Sentence 1 and 4)\\nE: Inhibition of the recovery process from DNA damage (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, Not(C))\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Not(Recovery from DNA damage))\\n--------\\nImplies(B, C)\\nImplies(PARP1/2 are involved in polyADP-ribosylation, Recovery from DNA damage)\\n--------\\nImplies(Not(C), D)\\nImplies(Not(Recovery from DNA damage), Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(A, E)\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Inhibition of the recovery process from DNA damage)\\n--------\\nImplies(E, D)\\nImplies(Inhibition of the recovery process from DNA damage, Targeting tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(A, Not(B))\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Not(PARP1/2 are involved in polyADP-ribosylation))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(Targeting tumor-specific defects in DNA repair), Not([PARP1/2] inhibitors disrupt polyADP-ribosylation))\\n--------\\nImplies(B, Not(A))\\nImplies(PARP1/2 are involved in polyADP-ribosylation, Not([PARP1/2] inhibitors disrupt polyADP-ribosylation))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a logical relation that [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n(* This is consistent with the logical relation Implies(A, D), where A is [PARP1/2] inhibitors disrupt polyADP-ribosylation and D is targeting tumor-specific defects in DNA repair. *)\\n(* Explanation 3 also supports this by stating that disrupting polyADP-ribosylation by [PARP1/2] inhibitors is a mechanism to target tumor-specific defects in DNA repair. *)\\n(* Therefore, we can infer that the inhibitors target the defects through the role of PARP1/2 in recovery from DNA damage. *)\\nthen have \"Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\" sledgehammer', 'solving time': 103.50979709625244, 'proof tactics': [], 'code': 'theory clinical_91_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitors :: \"entity \u21d2 bool\"\\n  AnticancerAgents :: \"entity \u21d2 bool\"\\n  Defects :: \"entity \u21d2 bool\"\\n  DNARepair :: \"entity \u21d2 bool\"\\n  ClassOf :: \"entity \u21d2 entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Interfere :: \"event \u21d2 bool\"\\n  RoleOf :: \"event \u21d2 entity \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  Disrupt :: \"event \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  PARP2 :: \"entity \u21d2 bool\"\\n  PolyADPRibosylation :: \"entity \u21d2 bool\"\\n  Involved :: \"entity \u21d2 entity \u21d2 bool\"\\n  Crucial :: \"entity \u21d2 bool\"\\n  Mechanism :: \"event \u21d2 bool\"\\n  Leads :: \"event \u21d2 event \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  TumorCells :: \"entity \u21d2 bool\"\\n  Inhibition :: \"event \u21d2 bool\"\\n  RecoveryProcess :: \"event \u21d2 bool\"\\n  Essential :: \"entity \u21d2 bool\"\\n  Involves :: \"event \u21d2 bool\"\\n  RepairMechanisms :: \"event \u21d2 bool\"\\n  Disrupted :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage, specifically through disrupting polyADP-ribosylation *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2. Inhibitors x \u2227 AnticancerAgents y \u2227 Defects z \u2227 DNARepair w \u2227 ClassOf x y \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 In z w \u2227 Interfere e2 \u2227 Agent e2 x \u2227 RoleOf e2 w \u2227 Through e2 w \u2227 Disrupt e2\"\\n\\n(* Explanation 2: PARP1 and PARP2 are both involved in polyADP-ribosylation, a process crucial for recovery from DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. PARP1 x \u2227 PARP2 y \u2227 PolyADPRibosylation z \u2227 Involved x z \u2227 Involved y z \u2227 Crucial z\"\\n\\n(* Explanation 3: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly interferes with the role of PARP1/2 in recovery from DNA damage, which is a mechanism to target tumor-specific defects in DNA repair *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Inhibitors x \u2227 PolyADPRibosylation y \u2227 Defects z \u2227 DNARepair w \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Interfere e2 \u2227 Agent e2 x \u2227 RoleOf e2 w \u2227 Mechanism e2 \u2227 Target e2 \u2227 Patient e2 z\"\\n\\n(* Explanation 4: Interfering with the role of PARP1/2 in recovery from DNA damage directly leads to the targeting of tumor-specific defects in DNA repair, as it prevents the repair of DNA damage in tumor cells *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2. RoleOf e1 x \u2227 DNARepair y \u2227 Defects z \u2227 TumorCells w \u2227 Interfere e1 \u2227 Agent e1 x \u2227 Leads e1 e2 \u2227 Target e2 \u2227 Patient e2 z \u2227 Prevents e2 \u2227 Repair e2 \u2227 In w z\"\\n\\n(* Explanation 5: Disrupting polyADP-ribosylation by [PARP1/2] inhibitors directly leads to the inhibition of the recovery process from DNA damage, thereby targeting tumor-specific defects in DNA repair through the role of PARP1/2 in recovery from DNA damage *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e1 e2. Inhibitors x \u2227 PolyADPRibosylation y \u2227 Defects z \u2227 DNARepair w \u2227 Disrupt e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Leads e1 e2 \u2227 Inhibition e2 \u2227 RecoveryProcess e2 \u2227 Target e2 \u2227 Patient e2 z \u2227 Through e2 w\"\\n\\n(* Explanation 6: The role of PARP1/2 in recovery from DNA damage is essential for targeting tumor-specific defects, as it involves the repair mechanisms that are disrupted by [PARP1/2] inhibitors *)\\naxiomatization where\\n  explanation_6: \"\u2203x y z e1 e2. RoleOf e1 x \u2227 DNARepair y \u2227 Defects z \u2227 Essential x \u2227 Target e1 \u2227 Patient e1 z \u2227 Involves e2 \u2227 RepairMechanisms e2 \u2227 Disrupted e2 \u2227 Agent e2 x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\"\\n  (* Hypothesis: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage *)\\n  shows \"\u2203x y z e. Inhibitors x \u2227 Defects y \u2227 DNARepair z \u2227 Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\"\\nproof -\\n  (* From the premise, we have known information about inhibitors, defects, and DNA repair. *)\\n  from asm have \"Inhibitors x \u2227 Defects y \u2227 DNARepair z\" <ATP>\\n  (* Explanation 1 provides a logical relation that [PARP1/2] inhibitors target tumor-specific defects in DNA repair by interfering with the role of PARP1/2 in recovery from DNA damage. *)\\n  (* This is consistent with the logical relation Implies(A, D), where A is [PARP1/2] inhibitors disrupt polyADP-ribosylation and D is targeting tumor-specific defects in DNA repair. *)\\n  (* Explanation 3 also supports this by stating that disrupting polyADP-ribosylation by [PARP1/2] inhibitors is a mechanism to target tumor-specific defects in DNA repair. *)\\n  (* Therefore, we can infer that the inhibitors target the defects through the role of PARP1/2 in recovery from DNA damage. *)\\n  then have \"Target e \u2227 Agent e x \u2227 Patient e y \u2227 In y z \u2227 Through e z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors disrupt polyADP-ribosylation (from Explanatory Sentence 1)\\nB: PARP1 and PARP2 are involved in polyADP-ribosylation (from Explanatory Sentence 2)\\nC: Recovery from DNA damage (from Explanatory Sentence 1 and 2)\\nD: Targeting tumor-specific defects in DNA repair (from Explanatory Sentence 1)\\n\\nLogical Relations:\\nImplies(A, Not(C))\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Not(Recovery from DNA damage))\\n--------\\nImplies(Not(C), D)\\nImplies(Not(Recovery from DNA damage), Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(B, C)\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, Recovery from DNA damage)\\n--------\\nImplies(A, D)\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(C, D)\\nImplies(Recovery from DNA damage, Targeting tumor-specific defects in DNA repair)\\n--------\\n\\nDerived Implications:\\nImplies(B, D)\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(PARP1 and PARP2 are involved in polyADP-ribosylation), Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(A, Not(B))\\nImplies([PARP1/2] inhibitors disrupt polyADP-ribosylation, Not(PARP1 and PARP2 are involved in polyADP-ribosylation))\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(Targeting tumor-specific defects in DNA repair), Not(PARP1 and PARP2 are involved in polyADP-ribosylation))\\n--------\\nImplies(Not(D), A)\\nImplies(Not(Targeting tumor-specific defects in DNA repair), [PARP1/2] inhibitors disrupt polyADP-ribosylation)\\n--------\\nImplies(Not(A), D)\\nImplies(Not([PARP1/2] inhibitors disrupt polyADP-ribosylation), Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(B, Not(A))\\nImplies(PARP1 and PARP2 are involved in polyADP-ribosylation, Not([PARP1/2] inhibitors disrupt polyADP-ribosylation))\\n--------\\nImplies(Not(D), D)\\nImplies(Not(Targeting tumor-specific defects in DNA repair), Targeting tumor-specific defects in DNA repair)\\n--------\\nImplies(Not(D), B)\\nImplies(Not(Targeting tumor-specific defects in DNA repair), PARP1 and PARP2 are involved in polyADP-ribosylation)\\n--------\\n'}"
        ]
    }
}